Full Text View
Tabular View
No Study Results Posted
Related Studies
Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)
This study has been completed.
Study NCT00886886   Information provided by University Hospital, Basel, Switzerland

First Received on April 22, 2009.   Last Updated on January 24, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mood Disorder
Substance-related Disorders
Amphetamine-related Disorders
Additional conditions recognized in this trial
Mood Disorders
More general conditions related to this trial
Mental Disorders
Interventions listed in this trial
MDMA
Reboxetine, 8 mg
Placebo
Additional drug interventions recognized in this trial
N-Methyl-3,4-methylenedioxyamphetamine
Reboxetine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Hallucinogens
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Therapeutic Uses
Sponsors listed in this trial
University Hospital, Basel, Switzerland


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services